Skip to main content

Commentary by Theresa L. Werner, MD, Ovarian Cancer Site Editor for JNCCN 360

Over the past few years, the use of PARP inhibitors has substantially expanded options for maintenance therapy in ovarian cancer, and these agents have been included in the current version of the NCCN Clinical Practice Guidelines in Oncology.1 We have a better understanding of ovarian cancer biology—including the importance of germline and somatic BRCA mutations, as well as the role of homologous recombination deficiency (HRD) in tumors—and the potential benefit of new therapies.